Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872321 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2869499 | 0.85 | MAPT (0.45) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2876077 | 0.84 | GAA (0.44) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2871765 | 0.84 | GAA (0.47) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2875815 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2869379 | 0.82 | GAA (0.42) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL4838382 | 0.81 | KDM4E (0.47) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2872252 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2871365 | 0.81 | GAA (0.43) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2872368 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | claimed |
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | MMP12, MMP13, MMP9 | ALDH1A1 540/4885KDM4E 495/4885GAA 440/4885 |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | MMP12, PDE12, MMP13 | ALDH1A1 441/4885KDM4E 553/4885GAA 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.